Effects of dibenzazepine compounds on Nav1.2 channels and neuronal network activity: A systematic comparison
Voltage-gated Na<sup>+</sup> channels are critical therapeutic targets of anti-seizure medications. The anti-seizure medications such as carbamazepine (CBZ), oxcarbazepine (OXC) and eslicarbazepine acetate (ESL) of the dibenzazepine family are structurally similar, but a comparative analysis under identical conditions is lacking. Here, we rigorously compared their effects on biophysical properties of Na<sub>v</sub>1.2 Na <sup>+</sup> channels and effects on network properties in primary neuron cultures. HEK 293T cells stably expressing human Na<sub>v</sub>1.2 channels were employed to assess biophysical profiles using whole-cell patch clamp techniques. Additionally, the impact on neuronal networks in primary cortical neurons was evaluated using microelectrode array recordings. CBZ and OXC exhibited similar effects on voltage-dependent fast inactivation and recovery from inactivation. ESL and its active metabolite S-licarbazepine (S-Lic) also influenced fast inactivation, but their effects were less pronounced than those observed with CBZ. Notably, S-Lic exhibited comparatively small effects on use-dependent block. In these in vitro settings, all compounds had a subtle effect on slow inactivation. With regards to neuronal network activity, CBZ, OXC, and ESL induced substantial changes in spiking, bursting, and synchrony. S-Lic elicited significant and selective effects on network synchrony without effects on other parameters. In conclusion, CBZ, OXC and ESL exhibited similar activity profiles on properties of Na<sub>v</sub>1.2 channels and neuronal networks. The structurally similar S-Lic showed significantly less use-dependent blocking effect, and a selective effect on distributed network bursts. These results emphasize that structurally similar dibenzazepine anti-seizure medications can exhibit substantial differences in activity on the ion channel and network level.
Authors
- Susanne Schoch (ORCID: https://orcid.org/0000-0002-2046-2670)
- Kunihiko Araki (ORCID: https://orcid.org/0000-0002-0859-7046)
- Heinz Beck (ORCID: https://orcid.org/0000-0002-8961-998X)
- Thoralf Opitz (ORCID: https://orcid.org/0009-0001-2419-5004)
- Michael Wenzel (ORCID: https://orcid.org/0000-0002-6065-1660)
- Griselda Marku
- Merlin Schwering-Sohnrey
Institutions
- University of Bonn (DE)
- University Hospital Bonn (DE)
Publication Details
- Journal
- European Journal of Pharmacology
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1016/j.ejphar.2025.178147
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00